Elan, Biogen say FDA to extend review on Tysabri
Reuters - USA
... Quote, Profile, Research) and Biogen Idec (BIIB.O: Quote, Profile, Research) faced a fresh delay in getting their multiple sclerosis treatment Tysabri back to ...

Elan Says US Regulator Delays Tysabri for 90 Days (Update2)
Bloomberg - USA
... said US regulators delayed the possible return of their multiple sclerosis treatment Tysabri to study the companies' safety plan for resuming sales of the ...

FDA to extend review on Tysabri - companies
Reuters - USA
... Elan (ELN.I: Quote, Profile, Research) and Biogen Idec (BIIB.O: Quote, Profile, Research) it will extend its regulatory review of their Tysabri treatment for ...

Makers of MS drug Tysabri say FDA delaying verdict on drug's sale ...
Canada.com - Hamilton,Ontario,Canada
... of a suspended multiple sclerosis drug said Wednesday that American regulators have delayed until June their decision on whether to permit Tysabri to return to ...

FDA to extend Tysabri review
MarketWatch - USA
LONDON (MarketWatch) -- The US Food and Drug Administration has decided to extend its review of the multiple sclerosis drug Tysabri by up to 90 days, Elan and ...

FDA says Tysabri review a high priority
Reuters - USA
WASHINGTON (Reuters) - A review of Biogen Idec and Elan's bid to return multiple sclerosis drug Tysabri to the market "continues to be a high priority," the ...
See all stories on this topic

New Speedbump for Tysabri
TheStreet.com - USA
... Elan (ELN:NYSE - commentary - research - Cramer's Take) suffered a setback Wednesday when the FDA said it wanted another 90 days to review Tysabri, the multiple ...

Elan, Biogen say FDA to extend review on Tysabri
ABC News - USA
... Reuters) - The US Food and Drug Administration has told drug firms Elan and Biogen Idec it will extend its regulatory review of their Tysabri treatment for ...

Elan Says US Regulator Delays Tysabri for 90 Days (Update3)
Bloomberg - USA
... said US regulators delayed the possible return of the multiple sclerosis drug Tysabri to review the companies' plan to prevent a rare side effect that killed ...